Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer
- 1 January 2007
- journal article
- clinical trial
- Published by S. Karger AG in Oncology
- Vol. 73 (5-6), 407-414
- https://doi.org/10.1159/000136796
Abstract
Background: Patients with metastatic breast cancer (MBC) are increasingly exposed to anthracyclines and taxanes either during treatment of primary breast cancer or during initial therapy of metastatic disease. The combination of gemcitabine and carboplatin was therefore investigated as an anthracycline- and taxane-free treatment option. Patients and Methods: MBC patients previously treated with chemotherapy were enrolled in a multicenter phase II study. Treatment consisted of gemcitabine (1,000 mg/m2 i.v. on days 1 and 8) and carboplatin (AUC 4 i.v. on day 1) applied every 3 weeks. Results: Thirty-nine patients were recruited, and a total of 207 treatment cycles were applied with a median of 5 cycles per patient. One complete response and 11 partial responses were observed for an overall response rate of 31% (95% CI: 17–48%). Twelve patients (31%) had stable disease. Median time to progression was 5.3 months (95% CI: 2.6–6.7 months) and median overall survival from start of treatment was 13.2 months (95% CI: 8.7–16.7 months). Grade 3/4 hematological toxicity included leukopenia (59%/5%), thrombocytopenia (26%/23%) and anemia (10%/0%). Nonhematological toxicity was rarely severe. Conclusion: Combination chemotherapy with gemcitabine and carboplatin is an effective and generally well-tolerated treatment option for intensively pretreated patients with MBC. Due to a considerable incidence of severe thrombocytopenia it would be reasonable to consider starting gemcitabine at the lower dose level of 800 mg/m2.Keywords
This publication has 28 references indexed in Scilit:
- Phase II study of gemcitabine plus cisplatin in metastatic breast cancerAnti-Cancer Drugs, 2006
- A Phase II Trial of Gemcitabine in Patients with Metastatic Breast Cancer Previously Treated with an Anthracycline and TaxaneClinical Breast Cancer, 2005
- Phase II Study of Gemcitabine Plus Cisplatin in Patients With Metastatic Breast CancerAmerican Journal of Clinical Oncology, 2005
- Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancerActa Oncologica, 2004
- Capecitabine Monotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast CancerMedical Oncology, 2004
- Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and TaxaneJournal of Korean Medical Science, 2004
- Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancerThe Breast, 2000
- Comprehensive Criteria for Assessing Therapy-Induced ToxicityCancer Investigation, 1990
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958